Phase I study of docetaxel, oxaliplatin, and capecitabine as first-line therapy to patients with advanced gastroesophageal cancer.

K. Schønnemann,M. Andersen,M. Yilmaz,H. Jensen,L. Vestermark,P. Pfeiffer

DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.e15613

IF: 45.3

2016-09-22

Journal of Clinical Oncology

Abstract:e15613 Background: Previously, epirubicin, cisplatin, and 5-FU (ECF) were often recommended as first line therapy to patients (pts) with advanced gastro-esophageal cancer (GE). If cisplatin is substituted by oxaliplatin (E) and 5-FU by capecitabine (X) this regimen can easily be administered with comparable efficacy and lower toxicity. In addition, recent studies have shown that efficacy can be improved by adding docetaxel (T) to CF. We therefore initiated a phase I trial of docetaxel, short-time infusion of oxaliplatin and continuously capecitabine (TEX) as first line therapy to establish the recommended dose for further therapy. METHODS Pts were enrolled in cohorts of 3 at each dose level ( Table ). All pts had non resectable histologically GE adenocarcinoma. No pts had received prior chemotherapy. Therapy was given day 1 with escalating doses of docetaxel (60 mg/m2to 75 mg/m2, as a 60 minutes infusion), capecitabine (1000 to1250 mg/m2/day continuously) and oxaliplatin (85 to 130 mg/m2 as a 30 minutes infusion). Cycles were repeated every 3 weeks for a maximum of 8 cycles. Toxicity was evaluated according to NCIC-CTC 3.0. DLT was evaluated after the first TEX cycle and defined as non-hematological toxicity grade ≥ 3, neutropenia grade 4 or febrile neutropenia more than 7 days. RESULTS From June 2007 to July 2008, 16 consecutive pts were treated with escalating doses of TEX. Median age was 59 years (43-74), median performance status was 1 (0-1). At dose level 5, two of 4 pts had DTL (1 pt had grade 3 vomiting and nausea and 1 pt had grade 3 nausea, vomiting and diarrhea). In addition 3 of 4 pts had neutropenia grade 4 without fever at dose level 5. Presently, 12 pts are still alive. CONCLUSIONS First line taxotere, oxaliplatin and capecitabine every 3 weeks is easily administered in an out-patient setting but with substantial GI and haematological toxicity at dose level 5. An additional 6 pts will be included at dose level 4 to confirm tolerability at dose level 4. [Table: see text] No significant financial relationships to disclose.